Your browser doesn't support javascript.
loading
First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers.
Komdeur, Fenne L; Singh, Amrita; van de Wall, Stephanie; Meulenberg, Janneke J M; Boerma, Annemarie; Hoogeboom, Baukje Nynke; Paijens, Sterre T; Oyarce, Cesar; de Bruyn, Marco; Schuuring, Ed; Regts, Joke; Marra, Ruben; Werner, Naomi; Sluis, Jessica; van der Zee, Ate G J; Wilschut, Jan C; Allersma, Derk P; van Zanten, Coba J; Kosterink, Jos G W; Jorritsma-Smit, Annelies; Yigit, Refika; Nijman, Hans W; Daemen, Toos.
Afiliação
  • Komdeur FL; Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Singh A; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • van de Wall S; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Meulenberg JJM; ViciniVax BV, Meditech Center, Groningen, the Netherlands.
  • Boerma A; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Hoogeboom BN; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Paijens ST; Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Oyarce C; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • de Bruyn M; Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Schuuring E; Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Regts J; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Marra R; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Werner N; Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Sluis J; Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • van der Zee AGJ; Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Wilschut JC; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Allersma DP; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • van Zanten CJ; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Kosterink JGW; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Jorritsma-Smit A; Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Yigit R; Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Nijman HW; Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Daemen T; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Electronic address: c.a.h.h.daemen@umcg.nl.
Mol Ther ; 29(2): 611-625, 2021 02 03.
Article em En | MEDLINE | ID: mdl-33160073
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vírus da Floresta de Semliki / Vacinas Anticâncer / Infecções por Papillomavirus / Vacinas contra Papillomavirus / Vetores Genéticos / Neoplasias Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Mol Ther Assunto da revista: BIOLOGIA MOLECULAR / TERAPEUTICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vírus da Floresta de Semliki / Vacinas Anticâncer / Infecções por Papillomavirus / Vacinas contra Papillomavirus / Vetores Genéticos / Neoplasias Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Mol Ther Assunto da revista: BIOLOGIA MOLECULAR / TERAPEUTICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda